Abiopharma

🔍 Zygmont Chester Stanley III (Executive)

Company: REVELATION BIOSCIENCES, INC. (REVB)

Report Date: 2026-01-08

Detailed Transactions and Holdings:

• Acquired 78,145 shares of Common Stock at $0.9 per share (Direct)
  Date: 2026-01-08 | Code: A | equity_swap_involved: false | shares_owned_after: 473,790.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-08 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 395,640.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-08 | Code: H | nature_of_ownership: By LLC | shares_owned_after: 5.00 | Footnotes: F3

Footnotes:

• F1: Restricted Stock Units under the 2021 Equity Incentive Plan. Vests quarterly over two years from the date of grant.
• F2: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.
• F3: Shares are held by Czeslaw Capital Fund, LLC. Chester S Zygmont III is the sole manager of Czeslaw Capital Fund, LLC.